Long-awaited data from a confirmatory phase III study aimed at convincing regulators of the efficacy of twice-rejected Kiacta (eprodisate) in AA amyloidosis, ended up dealing a crushing blow to Bellus Health Inc., with top-line results Monday showing the five-year, event-driven trial missed the primary endpoint of slowing renal function decline in patients with the orphan disease.